{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:55:47Z","timestamp":1760547347097},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1093\/annonc\/mdf243","type":"journal-article","created":{"date-parts":[[2002,11,7]],"date-time":"2002-11-07T02:18:05Z","timestamp":1036635485000},"page":"1469-1478","source":"Crossref","is-referenced-by-count":48,"title":["A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma"],"prefix":"10.1016","volume":"13","author":[{"given":"T.R.J.","family":"Evans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Blackie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Raby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"Fullarton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Soukop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf243_bb0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/bjs.1800760604","article-title":"Gastric cancer \u2014a 25 year review","volume":"76","author":"Allum","year":"1989","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdf243_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","article-title":"Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer","volume":"72","author":"Murad","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.annonc.a058778","article-title":"Initial or delayed chemotherapy with best supportive care in advanced gastric cancer","volume":"5","author":"Glimelius","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bjc.1995.114","article-title":"Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer","volume":"71","author":"Pyrhonen","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a058932","article-title":"A phase II study in advanced gastro-oesophageal cancer using epuribicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)","volume":"5","author":"Findlay","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0035","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/bjs.1800811218","article-title":"Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma","volume":"81","author":"Highley","year":"1994","journal-title":"Br J Surgery"},{"key":"10.1093\/annonc\/mdf243_bb0040","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/1097-0142(19951115)76:10<1694::AID-CNCR2820761004>3.0.CO;2-K","article-title":"Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer report","volume":"76","author":"Zaniboni","year":"1995","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO.1997.15.1.261","article-title":"Randomised trial comparing epuribicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0050","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/bjc.1996.241","article-title":"A phase II study of continuous infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer","volume":"73","author":"Evans","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0055","first-page":"2081","article-title":"Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis","volume":"20","author":"Kikuyama","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf243_bb0060","first-page":"4363","article-title":"Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma","volume":"19","author":"Ogawa","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf243_bb0065","first-page":"4001","article-title":"The expression of thymidine phosphorylase and its correlation with angiogenesis in gastric adenocarcinoma","volume":"19","author":"Ikeguchi","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdf243_bb0070","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.bjc.6690719","article-title":"The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma","volume":"81","author":"Saito","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0075","first-page":"429","article-title":"Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer","volume":"4","author":"Takahashi","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf243_bb0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<545::AID-IJC12>3.0.CO;2-5","article-title":"Combined analysis of vascular endothelial growth factor and platelet-derived endothelial growth factor expression in gastric carcinoma","volume":"74","author":"Maeda","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0304-3835(96)04482-5","article-title":"Tumor angiogenesis and expression of thymidine phosphorylase\/platelet derived endothelial cell growth factor in human gastric carcinoma","volume":"108","author":"Tanigawa","year":"1996","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdf243_bb0090","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.1996.177","article-title":"Thymidine phosphorylase\/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma","volume":"73","author":"Maeda","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0095","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1349-7006.1996.tb00219.x","article-title":"Expression of thymidine phosphorylase in human gastric carcinoma","volume":"87","author":"Takebayashi","year":"1996","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdf243_bb0100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000011968","article-title":"Prediction of response to 5\u2032-deoxy-5-fluorouridine (5\u2032-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase\/platelet-derived endothelial cell growth factor","volume":"56","author":"Koizumi","year":"1999","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdf243_bb0105","first-page":"321","article-title":"The expression of thymidylate synthase and thymidine phosphorylase in the early-stage of gastric cancer","volume":"26","author":"Suda","year":"1999","journal-title":"Jpn J Cancer Chemother"},{"key":"10.1093\/annonc\/mdf243_bb0110","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2220::AID-CNCR4>3.0.CO;2-C","article-title":"The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma","volume":"88","author":"Shimaoka","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf243_bb0115","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","article-title":"Phase I and pharmacodynamic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer","volume":"16","author":"Mackean","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients","volume":"45","author":"Schuller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdf243_bb0125","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomised phase II study","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multi-center phase II study of capecitabine in paclitaxel\u2014refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"South West Oncology Group Standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdf243_bb0140","first-page":"941","article-title":"Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients","volume":"4","author":"Reigner","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf243_bb0145","first-page":"285","article-title":"Prolonged stable disease affects survival in patients with solid gastric tumour: analysis of phase II studies of doxifluridine","volume":"17","author":"Takahashi","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0150","first-page":"1021","article-title":"A phase III randomised study comparing oral doxifluridine and oral 5-fluorouracil after curative resection of gastric cancer","volume":"16","author":"Takiguchi","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0155","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf243_bb0160","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1023\/A:1008329822726","article-title":"Epirubicin, cisplatin, and oral UFT with leucovorin (ECU): a phase I\u2013II study in patients with advanced upper gastrointestinal tract cancer","volume":"10","author":"Seymour","year":"1999","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419638032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419638032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/9\/1469\/417007\/mdf243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:34:55Z","timestamp":1582184095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419638032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S0923753419638032"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf243","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}